ASPG and acute lymphoblastic leukemia: In their subsequent ALL trial, DFCI 05-001, patients were randomized to receive these 30-weeks of asparaginase therapy as either 30 weekly doses of native E. coli asparaginase 25,000 IU/m2 IM or 15 doses of PEG 2,500 IU/m2 IV given every other week.